Section: N/A ReadChanges --- title: When does patient need outweigh scientific rigor when approving experimental drugs? --- is a question related to the recent decision by the FDA to grant approval to an experimental Alzheimer's drug, Aducanumab, despite significant opposition from the scientific community [@Ix4D05E7]. When confronted with an intractable, widespread disease, when--if ever--is it acceptable to prematurely grant approval for a questionably effective treatment? ## Patient need Alzheimer's is a devastating disease with no known cure, and has had no new medications approved for its treatment since 2003. Consequently, there is a significant amount of despair and hopelessness associated with its diagnosis [@Tx452C9F]. ReadChanges
